{"id":"low-dose-hydroxyurea","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":null,"effect":"Macrocytosis"},{"rate":null,"effect":"Elevated uric acid levels"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydroxyurea is a ribonucleotide reductase inhibitor that promotes the production of fetal hemoglobin (HbF), which does not polymerize like sickle hemoglobin (HbS). By increasing HbF levels and reducing the proportion of HbS, the drug decreases hemolysis, vaso-occlusive crises, and organ damage in sickle cell disease. At low doses, it achieves therapeutic benefit while minimizing myelosuppression.","oneSentence":"Low-dose hydroxyurea increases fetal hemoglobin (HbF) production and reduces sickling of red blood cells by inhibiting ribonucleotide reductase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:35.168Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sickle cell disease (reduction of vaso-occlusive crises and acute chest syndrome)"}]},"trialDetails":[{"nctId":"NCT06526117","phase":"PHASE4","title":"Stroke Prevention in Nigeria 2 Trial","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2024-08-05","conditions":"Sickle Cell Disease, Stroke","enrollment":220},{"nctId":"NCT03165734","phase":"PHASE3","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-06-26","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":399},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT04229979","phase":"PHASE3","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-02-08","conditions":"Acute Myeloid Leukemia","enrollment":127},{"nctId":"NCT04808778","phase":"","title":"Stroke Prevention in Young Adults With Sickle Cell Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-05-17","conditions":"Sickle Cell Disease, Sickle Cell Anemia, Stroke, Ischemic","enrollment":250},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT06005324","phase":"PHASE1","title":"Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-12-18","conditions":"HPV-Negative Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT02577406","phase":"PHASE3","title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-12-30","conditions":"Leukemia, Myeloid, Isocitrate Dehydrogenase","enrollment":319},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT01499888","phase":"PHASE1, PHASE2","title":"Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2011-11-11","conditions":"Sickle Cell Disease","enrollment":45},{"nctId":"NCT02258659","phase":"PHASE2","title":"Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-09-22","conditions":"Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx","enrollment":62},{"nctId":"NCT06503458","phase":"","title":"A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants","status":"TERMINATED","sponsor":"Sanguine Biosciences","startDate":"2022-01-19","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":52},{"nctId":"NCT05407805","phase":"","title":"A Study to Learn About Sickle Cell Disease In Adult Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-02-10","conditions":"Sickle Cell Disease","enrollment":98},{"nctId":"NCT06239389","phase":"PHASE2","title":"Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.","status":"COMPLETED","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2021-09-01","conditions":"Beta-Thalassemia","enrollment":24},{"nctId":"NCT01387763","phase":"PHASE3","title":"A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms","status":"COMPLETED","sponsor":"Thomas Stauffer Larsen","startDate":"2012-01","conditions":"Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis","enrollment":202},{"nctId":"NCT03651102","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia","status":"COMPLETED","sponsor":"Blood Diseases Clinic","startDate":"2018-01-01","conditions":"Thalassemia","enrollment":654},{"nctId":"NCT02675790","phase":"PHASE3","title":"Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-01","conditions":"Sickle Cell Disease, Sickle Cell Anemia, Stroke","enrollment":120},{"nctId":"NCT05132270","phase":"PHASE2, PHASE3","title":"Clinical Experience of Thalidomide in Thalassemic Patients","status":"COMPLETED","sponsor":"Children's Hospital Karachi","startDate":"2020-01-01","conditions":"Thalassemia, Beta","enrollment":135},{"nctId":"NCT01597401","phase":"PHASE1","title":"A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2012-05-12","conditions":"Sickle Cell Disease","enrollment":19},{"nctId":"NCT01801423","phase":"NA","title":"Sickle Cell Disease - Stroke Prevention in Nigeria Trial","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2013-04-24","conditions":"Sickle Cell Anemia, Sickle Cell Disease, Stroke","enrollment":29},{"nctId":"NCT02560935","phase":"PHASE3","title":"Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-07-19","conditions":"Sickle Cell Disease, Stroke","enrollment":440},{"nctId":"NCT01895361","phase":"PHASE2","title":"Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises","status":"COMPLETED","sponsor":"Reprixys Pharmaceutical Corporation","startDate":"2013-07","conditions":"Sickle Cell Disease","enrollment":198},{"nctId":"NCT00055874","phase":"PHASE3","title":"Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2002-06","conditions":"Leukemia","enrollment":1551},{"nctId":"NCT00152113","phase":"PHASE1","title":"Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-04","conditions":"Sickle Cell Disease","enrollment":5},{"nctId":"NCT00940784","phase":"PHASE2","title":"Clopidogrel and Aspirin for the Treatment of Polycythemia Vera","status":"WITHDRAWN","sponsor":"Ronald Hoffman","startDate":"2009-06","conditions":"Polycythemia Vera","enrollment":""},{"nctId":"NCT00002869","phase":"PHASE3","title":"Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia","status":"UNKNOWN","sponsor":"Medical Research Council","startDate":"1995-04","conditions":"Leukemia","enrollment":800},{"nctId":"NCT00615927","phase":"PHASE2","title":"Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-02","conditions":"Glioblastoma, Gliosarcoma","enrollment":64},{"nctId":"NCT01645124","phase":"PHASE3","title":"Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)","status":"TERMINATED","sponsor":"Consorzio Mario Negri Sud","startDate":"2008-05","conditions":"Polycythemia Vera","enrollment":365},{"nctId":"NCT00040677","phase":"PHASE2","title":"A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.","status":"COMPLETED","sponsor":"Icagen","startDate":"2002-02","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hydrea"],"phase":"phase_3","status":"active","brandName":"Low Dose Hydroxyurea","genericName":"Low Dose Hydroxyurea","companyName":"Vanderbilt University Medical Center","companyId":"vanderbilt-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose hydroxyurea increases fetal hemoglobin (HbF) production and reduces sickling of red blood cells by inhibiting ribonucleotide reductase. Used for Sickle cell disease (reduction of vaso-occlusive crises and acute chest syndrome).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}